Programmed pH-responsive core–shell nanoparticles for precisely targeted therapy of ulcerative colitis

Zhang, Guangshuai; Han, Wen; Zhao, Peixu; Wang, Zijun; Li, Mo; Sui, Xiaofan; Liu, Yanhua; Tian, Baocheng; Zhang, He; Fu, Qiang

doi:10.1039/d2nr04968f

“…5A). 102 In addition to using combinations of Eudragit derivatives, a single material can also be used as a coating to prepare pH-responsive nanoparticles. Feng et al developed ES100/HA/CS nanoparticles (SK@SAC) loaded with shikonin (SK) as an oral drug delivery system for treating colitis in mice.…”

Section: Ph Responsive Nps Drug Delivery Systemsmentioning

confidence: 99%

“…Reproduced with permission. 102 Copyright 2023, Royal Society of Chemistry Publishing Group. (B) XA pH-responsive and colitis-targeted nanoparticle loaded with shikonin for the oral treatment of inflammatory bowel disease in mice.…”

Section: Ph Responsive Nps Drug Delivery Systemsmentioning

confidence: 99%

Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances

Hu,

Zhao,

Xu

et al. 2024

J. Mater. Chem. B

5

0

View full text Add to dashboard Cite

show abstract

“…Both drug carriers, gelatin/chitosan/hydroxyapatite [226] and folate-decorated alginate/polydopamine/paclitaxel (FA-Alg/PDA/Ptx) [227], used CuZn as biosensors in targeted therapy that demonstrated pH sensitivity and precise delivery of antitumor efficacy [228]. This FA-Alg/PDA/Ptx drug carrier had good encapsulation, loading, and IC50 efficiencies of 75.2 ± 1.54 %, 18.54 ± 2.31 %, and 150 ± 2.58 μg/mL, respectively, indicating remarkable efficiency and drug potency [227].…”

Section: Challenges and Futurementioning

confidence: 99%

Combining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy

Zaidi¹,

Miskon²

2023

Preprint

0

View full text Add to dashboard Cite

Due to its built-up chemoresistance after prolonged usage, the demand for replacing platinum in metal-based drugs (MBD) is rising. The first MBD approved by the FDA for cancer therapy was cisplatin in 1978. Even after nearly four and a half decades of trials, there has been no significant improvement in osteosarcoma (OS) therapy. In fact, many MBD have been developed, but the chemoresistance problem raised by platinum remains unresolved. This motivates us to elucidate the possibilities of the copper and zinc (CuZn) combination to replace platinum in MBD. Thus, the anti-chemoresistance properties of CuZn and their physiological functions for OS therapy are highlighted. Herein, we summarise their chelators, main organic solvents, and ligand functions in their structures that are involved in anti-chemoresistance properties. Through this review, it is rational to discuss their ligands’ roles as biosensors in drug delivery systems. Hereafter, an in-depth understanding of their redox and photoactive function relationships is provided. The disadvantage is that the other functions of biosensors cannot be elaborated on here. As a result, this review is being developed, which is expected to intensify OS drugs with higher cure rates. Nonetheless, this advancement intends to solve the major chemoresistance obstacle towards clinical efficacy.

show abstract

“…Both drug carriers, gelatin/chitosan/hydroxyapatite [ 227 ] and folate-decorated Alg/polydopamine/paclitaxel (FA-Alg/PDA/Ptx) [ 228 ], used CuZn as biosensors in targeted therapy that demonstrated pH sensitivity and precise delivery of antitumor efficacy [ 229 ]. This FA-Alg/PDA/Ptx drug carrier had good encapsulation, loading, and IC 50 efficiencies of 75.2 ± 1.54%, 18.54 ± 2.31%, and 150 ± 2.58 μg/mL, respectively, indicating remarkable efficiency and drug potency [ 228 ].…”

Section: Challenges and Futurementioning

confidence: 99%

Combining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy

Zaidi

¹

,

Miskon

²

2023

Molecules

16

0

View full text Add to dashboard Cite

Due to its built-up chemoresistance after prolonged usage, the demand for replacing platinum in metal-based drugs (MBD) is rising. The first MBD approved by the FDA for cancer therapy was cisplatin in 1978. Even after nearly four and a half decades of trials, there has been no significant improvement in osteosarcoma (OS) therapy. In fact, many MBD have been developed, but the chemoresistance problem raised by platinum remains unresolved. This motivates us to elucidate the possibilities of the copper and zinc (CuZn) combination to replace platinum in MBD. Thus, the anti-chemoresistance properties of CuZn and their physiological functions for OS therapy are highlighted. Herein, we summarise their chelators, main organic solvents, and ligand functions in their structures that are involved in anti-chemoresistance properties. Through this review, it is rational to discuss their ligands’ roles as biosensors in drug delivery systems. Hereafter, an in-depth understanding of their redox and photoactive function relationships is provided. The disadvantage is that the other functions of biosensors cannot be elaborated on here. As a result, this review is being developed, which is expected to intensify OS drugs with higher cure rates. Nonetheless, this advancement intends to solve the major chemoresistance obstacle towards clinical efficacy.

show abstract

Programmed pH-responsive core–shell nanoparticles for precisely targeted therapy of ulcerative colitis

Abstract: pH-responsive nanotherapeutics were recently developed for the treatment of ulcerative colitis (UC). However, they target the entire colon rather than the UC site, which leads to insufficient accumulation in inflamed...

Cited by 18 publications

References 26 publications

Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances

Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances

Combining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy

Combining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy

Contact Info

Product

Resources

About